Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria
about
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorTicagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromesDual antiplatelet therapy: optimal timing, management, and durationTicagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agentManaging Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial FibrillationThe 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trialCardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialComparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION RegistryPharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised cTicagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyStandardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research ConsortiumTicagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisBaseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndromeGrowth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major BleedingDoes it help that efficacy has been proven once we start discussing (added) benefit?Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome.Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.New antithrombotic drugs.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonistEfficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.Review: Antiplatelet drugs: what comes next?Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.Antiplatelet therapy and vascular disease: an update.Ticagrelor: a review of its use in the management of acute coronary syndromes.Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
P2860
Q24605508-92B36711-E6AA-489D-89FC-A59B808DEE79Q24631111-CE02E3E5-2295-4E5A-865F-0AD2A28A154CQ26741055-636874C1-A3BB-41ED-8A06-CC87F4485391Q26829967-42CA6157-CD6C-4C01-B617-100BF19D52F0Q28080247-7EAEF9D0-388C-4B2F-A966-F27A3F2FB823Q30513934-C132300E-D04C-44D9-9A1F-B010FE43CCD1Q30821177-DCA9CE7A-C5E0-40E4-BB37-5EABEDA705BDQ33699370-E0CE29F8-6178-4EB0-927A-74F8DE2D9D92Q33755410-E6D7BCC4-1C77-4D09-9078-69C9B786EEA8Q33893906-DAE654B3-987A-421C-9E36-DC59E98E380DQ34019342-1EC0DE7F-42D6-44EB-B980-54DC88579A6CQ34043989-6D693878-005D-41E0-8574-DC986DD51F15Q34305843-D22069D3-B2BA-4468-A82A-7C30FDDA6385Q34404150-0333754C-70EA-49A9-8200-DB8D072B37E4Q34456208-1F106FBA-2047-478C-9850-90F677AEF0DDQ34492675-3BD40177-F507-455A-BDF2-26AD5F62ADC3Q35051753-E8047315-5944-431D-871F-146361D5101EQ35802189-9BB7BDCA-5985-4D8E-9E19-87301516DEABQ36054209-0E1E5AEA-92AB-42B4-8080-2BAA12E129FAQ36062323-C4C13E1E-1AD0-44E2-89C6-B848D424494AQ36089473-37CD5E69-2118-4FDB-824D-05C16D901C78Q36141930-5B1BFAA3-B90F-445C-B923-9FDE773723A6Q36327413-D8DBD894-9D56-4DC8-BB71-0F2CCF4E57B1Q36347479-37C19C1E-7146-4A07-8701-43B0998BE4FAQ36592792-67064B80-BA06-40B0-B3F7-5D9C8BD0B8AFQ37103506-A999A265-F594-40BF-877A-7427B054E58FQ37403998-258BF214-D9F9-4ACE-B368-93B991E3D6C7Q37530424-60EE43CC-3AD2-4E93-82C6-108C5EBBE1D5Q37552005-9E561C45-B5D3-43CC-BA08-6C97DABF5E44Q37685847-000BD8F5-BF34-4D9F-BFF6-0D33BAA6F584Q37688144-795E49BF-317E-47FD-A789-C57F94A28502Q37752222-CA9F8DCA-980B-43AB-B13F-BF7D371C1C71Q37799470-D05A98E7-A8CB-4BE4-9858-820CC0B0E5FDQ37807874-6191826B-FFFA-4F30-886F-A41145BD0979Q37809630-63D40C24-57E0-4740-8218-30F3576CA9B2Q37825548-BF725AF1-86F1-45CD-901F-D46E35F6AC6DQ37838100-128AD797-B129-457A-ADA3-65B8DC10D521Q37875063-452B0E4F-F963-40D1-AD3F-23974291E916Q37907902-7D7EB898-AB26-446A-96C7-733B204F4A56Q37959155-358E4860-783F-4308-8AB0-775059632841
P2860
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@en
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@nl
type
label
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@en
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@nl
prefLabel
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@en
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@nl
P2093
P50
P1476
Comparison of ticagrelor, the ...... patient Outcomes (PLATO) tria
@en
P2093
Allan Skene
Axel Akerblom
Christopher P Cannon
Hugo Katus
Richard Becker
Steen Husted
Stefan James
P304
P356
10.1016/J.AHJ.2009.01.003
P407
P577
2009-04-01T00:00:00Z